We are a multi-disciplinary team focusing on developing diagnostic and clinical decision support solutions for hematologic malignancies using artificial intelligence. Our co-founders Andrea, Kevin, and Jeremy provide a perfect synergy of data science, clinical medicine, and artificial intelligence expertise. Currently, we have developed a residual leukemia cell detection model (AHEAD-flow) that reduce the interpretation time from 20 minutes to 7 seconds and a relapse/mortality prediction model (AHEAD-mcap) with over 80% accuracy for acute leukemia.